Dosimetric Comparison of VMAT Alone and VMAT with HDR Brachytherapy Boost Using Clinical and Biological Dose Models in Localized Prostate Cancer
Current Oncology · 2025
DOI: 10.3390/curroncol32060360 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Current Oncology, 2025. Verfasst von Manuel Guhlich und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Brachytherapy, Radiotherapy, Intensity-Modulated. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Combining external beam radiotherapy (EBRT) with high-dose-rate (HDR) brachytherapy (BT) enables biologically effective dose escalation in prostate cancer. However, comparative evaluation of such regimens using radiobiological modeling remains limited.
Methods
Dose regimens based on clinical practice were analyzed using α/β values of 1.5 and 3 Gy for the prostate. Ten patients with available planning CT, pelvic MRI, and ultrasound-guided BT plans were retrospectively evaluated. Physical and biological dose distributions were recalculated for various EBRT and HDR-BT combinations. Biological effective dose (BED) values were determined for the prostate and organs at risk (OARs: anterior rectal wall, bladder base, urethra). Regimens yielding the highest ΔBED between prostate and OARs were considered most favorable.
Results
All regimens met clinical dose constraints. The most favorable ΔBED profiles for bladder and rectum were observed with HDR-BT regimens (2 × 15 Gy) combined with either 23 × 2 Gy or 15 × 2.5 Gy EBRT, independent of the assumed α/β value. EBRT-only regimens achieved superior urethral sparing, while higher HDR doses led to increased urethral exposure.
Conclusions
This study underscores the value of radiobiological modeling in differentiating and optimizing prostate cancer radiotherapy strategies. While the trade-offs between dose escalation and OAR sparing are clinically known, our biologically driven analysis provides a more quantitative foundation for selecting and tailoring combined EBRT/HDR-BT regimens in practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinic of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany.
- Department of Urology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany.
ORCID-Profile: Manuel Guhlich, Jann Fischer, Leif Hendrik Dröge, Martin Leu, Stefan Rieken, Annemarie Uhlig, Markus Anton Schirmer
Zitieren
APA
Guhlich, M., Knaus, O., Strauss, A., Fischer, L. A., Fischer, J., Bendrich, S., Donath, S., Dröge, L. H., Leu, M., Rieken, S., Uhlig, A., Schirmer, M. A., & Hille, A. (2025). Dosimetric Comparison of VMAT Alone and VMAT with HDR Brachytherapy Boost Using Clinical and Biological Dose Models in Localized Prostate Cancer. Current Oncology. https://doi.org/10.3390/curroncol32060360
Vancouver
Guhlich M, Knaus O, Strauss A, Fischer LA, Fischer J, Bendrich S, et al. Dosimetric Comparison of VMAT Alone and VMAT with HDR Brachytherapy Boost Using Clinical and Biological Dose Models in Localized Prostate Cancer. Current Oncology. 2025. doi:10.3390/curroncol32060360
BibTeX
@article{Guhlich2025,
author = {Guhlich, Manuel and Knaus, Olga and Strauss, Arne and Fischer, Laura Anna and Fischer, Jann and Bendrich, Stephanie and Donath, Sandra and Dröge, Leif Hendrik and Leu, Martin and Rieken, Stefan and Uhlig, Annemarie and Schirmer, Markus Anton and Hille, Andrea},
title = {Dosimetric Comparison of VMAT Alone and VMAT with HDR Brachytherapy Boost Using Clinical and Biological Dose Models in Localized Prostate Cancer},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32060360}
}
EUVIMED